Education
About Us
Working with TipRanks
Follow Us
Kala Pharmaceuticals (KALA)
:KALA
Total Valuation
Kala Pharmaceuticals has a market cap or net worth of $65.37M. The enterprise value is $28.99M.
Market Cap$65.37M
Enterprise Value$28.99M
Share Statistics
Kala Pharmaceuticals has 7,021,040 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding7,021,040
Owned by Insiders24.22%
Owned by Institutions47.68%
Financial Efficiency
Kala Pharmaceuticals’s return on equity (ROE) is -3.12 and return on invested capital (ROIC) is -83.23%.
Return on Equity (ROE)-3.12
Return on Assets (ROA)-0.69
Return on Invested Capital (ROIC)-83.23%
Return on Capital Employed (ROCE)-1.06
Revenue Per Employee0.00
Profits Per Employee-1.01M
Employee Count38
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kala Pharmaceuticals is ―. Kala Pharmaceuticals’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value3.11
Price to FCF―
Price to Operating Cash Flow-1.98
PEG Ratio―
Income Statement
In the last 12 months, Kala Pharmaceuticals had revenue of 0.00 and earned -38.51M in profits. Earnings per share was -6.98.
Revenue0.00
Gross Profit-259.00K
Operating Income-40.98M
Pretax Income-38.51M
Net Income-38.51M
EBITDA-40.98M
Earnings Per Share (EPS)-6.98
Cash Flow
In the last 12 months, operating cash flow was -25.88M and capital expenditures -20.00K, giving a free cash flow of -25.90M billion.
Operating Cash Flow-25.88M
Free Cash Flow-25.90M
Free Cash Flow per Share-3.69
Dividends & Yields
Kala Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.20
52-Week Price Change79.80%
50-Day Moving Average6.59
200-Day Moving Average6.15
Relative Strength Index (RSI)70.03
Average Volume (3m)158.45K
Important Dates
Kala Pharmaceuticals upcoming earnings date is Nov 17, 2025, After Close (Confirmed).
Last Earnings DateAug 8, 2025
Next Earnings DateNov 17, 2025
Ex-Dividend Date―
Financial Position
Kala Pharmaceuticals as a current ratio of 3.11, with Debt / Equity ratio of -347.60%
Current Ratio3.11
Quick Ratio3.11
Debt to Market Cap0.79
Net Debt to EBITDA0.46
Interest Coverage Ratio-7.09
Taxes
In the past 12 months, Kala Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Kala Pharmaceuticals EV to EBITDA ratio is -0.47, with an EV/FCF ratio of -0.66.
EV to Sales0.00
EV to EBITDA-0.47
EV to Free Cash Flow-0.66
EV to Operating Cash Flow-0.66
Balance Sheet
Kala Pharmaceuticals has $31.94M in cash and marketable securities with $11.14M in debt, giving a net cash position of -$20.80M billion.
Cash & Marketable Securities$31.94M
Total Debt$11.14M
Net Cash-$20.80M
Net Cash Per Share-$2.96
Tangible Book Value Per Share$2.23
Margins
Gross margin is -27.95%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-27.95%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Kala Pharmaceuticals is $13.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$13.00
Price Target Upside34.72% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast51.27%